North America Basal Cell and Squamous Cell Carcinoma Therapeutics Market Size, Share, and COVID-19 Impact Analysis, By Drug Class (Antineoplastic, Hedgehog Pathway Inhibitors, Monoclonal Antibodies, and Others), By Route of Administration (Topical, Parenteral, and Oral), By Distribution Channel (Online Pharmacies, Hospital Pharmacies, and Retail Pharmacies), and North America Basal Cell and Squamous Cell Carcinoma Therapeutics Market Insights, Industry Trend, Forecasts to 2033

North America Basal Cell and Squamous Cell Carcinoma Therapeutics Market Insights Forecasts to 2033

• The North America Basal Cell and Squamous Cell Carcinoma Therapeutics Market Size was valued at USD 1112.75 Million in 2023.
• The Market is Growing at a CAGR of 16.02% from 2023 to 2033
• The North America Basal Cell and Squamous Cell Carcinoma Therapeutics Market Size is Expected to Reach USD 4915.23 Million by 2033

The North America Basal Cell and Squamous Cell Carcinoma Therapeutics Market Size is Anticipated to reach USD 4915.23 Million by 2033, Growing at a CAGR of 16.02% from 2023 to 2033.

Market Overview.

The North America basal cell and squamous cell carcinoma therapeutics market focuses on treatments for common non-melanoma skin cancers, basal cell carcinoma (BCC), and squamous cell carcinoma (SCC), primarily through the utilization of medications like monoclonal antibodies, antineoplastics, and hedgehog pathway inhibitors for advanced cases. Basal and squamous cell skin cancers are the most common types, often linked to sun exposure. Basal cell carcinomas, which are 8 out of 10 skin cancers, develop in the basal cell layer, typically on sun-exposed areas like the face, head, neck, and arms. Squamous cell carcinomas, which are 2 out of 10 skin cancers, start in flat cells in the upper part of the epidermis and often appear on sun-exposed areas like the face, ears, neck, lips, arms, and backs of the hands. Non-melanoma skin cancer (NMSC) refers to basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of the skin. BCCs can be difficult to treat if they reach an advanced stage due to mutations in genes in the hedgehog pathway. These drugs target a protein in this pathway and are taken as capsules, typically once a day. Chemotherapy drugs are usually given through a vein with intravenous infusion and may include medications like cisplatin, 5-fluorouracil, or doxorubicin. Monoclonal antibodies (mAbs) are emerging as promising therapeutic agents for basal and squamous cell carcinoma, particularly in advanced or metastatic stages. In basal cell carcinoma, inhibitors targeting the Hedgehog signaling pathway, such as vismodegib and sonidegib, have shown efficacy. In squamous cell carcinoma, cemiplimab, a monoclonal antibody targeting the programmed cell death-1 (PD-1) receptor, has been approved for treating locally advanced or metastatic cases. Other mAbs like pembrolizumab and nivolumab are under investigation for their potential in squamous cell carcinoma.

The rising prevalence of basal cell and squamous cell carcinoma among North Americans escalates the need for BCC and SCC therapeutics, which results in market growth. For instance, the data provided by the American Cancer Society states that basal and squamous cell skin cancers are the most common types of skin cancer in the United States, with an estimated 5.4 million diagnosed annually. About 8 out of 10 are basal cell cancers, with squamous cell cancers occurring less frequently. The increase in these cancers is attributed to better skin cancer detection, increased sun exposure, and longer life expectancy. However, deaths from these cancers are not as standard, with estimates ranging from 2,000 to 8,000 people per year, primarily from squamous cell skin cancer.

Report Coverage

This research report categorizes the North America basal cell and squamous cell carcinoma therapeutics market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyzes the key growth drivers, opportunities, and challenges influencing the North America basal cell and squamous cell carcinoma therapeutics market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyzes their core competencies in each sub-segment of the North America basal cell and squamous cell carcinoma therapeutics market.

Driving Factors

Basal and squamous cell carcinomas are the most common types of skin cancer in North America, with millions of cases reported annually. Innovations in targeted therapies, immunotherapies, and personalized medicine are improving patient outcomes. Increased awareness campaigns and diagnostic tools lead to earlier detection and treatment. The aging demographic in North America contributes to higher incidences. Research and development efforts are introducing new drugs and treatment modalities, boosting market growth. Governments and private organizations are investing heavily in cancer research, leading to the development of innovative therapies. Therefore, these factors drive the market growth.

Restraining Factors

Costly advanced therapies such as monoclonal antibodies and hedgehog pathway inhibitors can restrict accessibility for certain patients and may result in negative side effects. Delayed market entry can also be attributed to a lack of awareness regarding non-surgical treatment options, and rigorous approval processes may impede market growth.

Market Segmentation

The North America basal cell and squamous cell carcinoma therapeutics market share is classified into drug class, route of administration, and distribution channel.

• The hedgehog pathway inhibitors segment held the largest market share in 2023 and is expected to grow at a significant CAGR during the forecast period.

The North America basal cell and squamous cell carcinoma therapeutics market is segmented by drug class into the antineoplastic, hedgehog pathway inhibitors, monoclonal antibodies, and others. Among these, the hedgehog pathway inhibitors segment held the largest market share in 2023 and is expected to grow at a significant CAGR during the forecast period. The segmental expansion is attributed to the first line of treatment, reduced tumor growth, and prevention of cancer's recurrence.

• The oral segment accounted for the largest share in 2023 and is predicted to grow at a significant CAGR during the forecast period.

The North America basal cell and squamous cell carcinoma therapeutics market is segmented by route of administration into topical, parenteral, and oral. Among these, the oral segment accounted for the largest share in 2023 and is predicted to grow at a significant CAGR during the forecast period. The segment growth is attributed to the ease of administration, patient compliance, reduced tumor volume, and rapid onset of action.

• The hospital pharmacies accounted for the largest share in 2023 and is expected to grow at a substantial CAGR during the forecast period.

The North America basal cell and squamous cell carcinoma therapeutics market is segmented by distribution channel into online pharmacies, hospital pharmacies, and retail pharmacies. Among these, the hospital pharmacies accounted for the largest share in 2023 and is expected to grow at a substantial CAGR during the forecast period. The sector growth is owing to rising adaptability of biologics for the treatment of non-melanoma cancer, increasing admission for the in-patient services, accessibility of the wide stock of non-melanoma carcinoma medications, providing discounts on the medications, and counselling and dispensing medications facilities.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the North America basal cell and squamous cell carcinoma therapeutics market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Bausch Health Companies Inc.
• Eli Lilly Company
• Regeneron Pharmaceuticals Inc.
• Merck and Co., Inc.
• Pfizer Inc.
• Novartis
• Amgen Inc.
• Sirnaomics, Inc.
• Replimune Group, Inc.
• DermBiont, Inc.
• Sanofi
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In January 2025, Regeneron Pharmaceuticals reported positive results from the Phase 3 C-POST trial, showing that adjuvant treatment with PD-1 inhibitor Libtayo® (cemiplimab) significantly improved disease-free survival (DFS) in patients with high-risk cutaneous squamous cell carcinoma (CSCC) after surgery.

Market Segment

This study forecasts revenue at North America, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the North America basal cell and squamous cell carcinoma therapeutics market based on the below-mentioned segments:

North America Basal Cell and Squamous Cell Carcinoma Therapeutics Market, By Drug Class

• Antineoplastic
• Hedgehog Pathway Inhibitors
• Monoclonal Antibodies
• Others

North America Basal Cell and Squamous Cell Carcinoma Therapeutics Market, By Route of Administration

• Topical
• Parenteral
• Oral

North America Basal Cell and Squamous Cell Carcinoma Therapeutics Market, By Distribution Channel

• Online Pharmacies
• Hospital Pharmacies
• Retail Pharmacies